Curis Gets Nasdaq Delisting Notice After Stock Closes Below $1

What happened

Curis, Inc., a Lexington, Massachusetts-based biotechnology company, disclosed in a Form 8-K filed November 6, 2026 that it received a letter from Nasdaq's Listing Qualifications Staff on November 2, 2026 notifying it that the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days.

That falls below the $1.00 minimum required for continued listing on the Nasdaq Capital Market under Listing Rule 5550(a)(2), known as the Bid Price Rule, according to the filing.

Curis said it intends to make a timely request for a new hearing before the Nasdaq Hearings Panel or a newly convened panel. The company said such a request will stay any further delisting actions. It also said there can be no assurance the appeal will succeed or that it will remain listed on Nasdaq.

Curis shares closed at $0.91 on the event date, up 7.06% from the prior close of $0.85, according to the price data.

Why no compliance period this time

Companies that fall below the $1 bid price normally get a compliance window to regain it. Curis does not get one here, and the filing explains why.

Curis effected a 1-for-20 reverse stock split on July 6, 2026. Under Listing Rule 5810(c)(3)(A)(iv), a company that has done a reverse split within the prior year — or splits totaling 250 shares to one or more within two years — is not eligible for the compliance period otherwise specified in Rule 5810(c)(3)(A).

The filing also says that, following a Nasdaq Hearings Panel decision dated July 24, 2026, Curis is subject to a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for one year.

What this means

A delisting determination is not the same as being delisted. It is Nasdaq's finding that a listing standard has been broken and its notice that it intends to remove the stock. The company can contest it by requesting a hearing before the Nasdaq Hearings Panel, and, as the filing states, making that request holds off further delisting steps while the appeal is pending.

The $1.00 bid price rule is a minimum-price standard, not a measure of company size or finances. A stock that trades below a dollar for a sustained stretch — here, 30 consecutive business days — fails it regardless of the company's assets or revenue.

A reverse stock split combines several shares into one, raising the price per share proportionally while leaving the company's overall value unchanged. Curis's 1-for-20 split on July 6, 2026 folded twenty old shares into one new one. That kind of split is often done to lift the quoted price above $1, but Nasdaq's rules treat a recent reverse split as a signal that the price problem was already known, and the company loses the standard compliance period as a result.

The Discretionary Panel Monitor is an extra layer. Having already been through a Hearings Panel process — the July 24, 2026 decision — Curis is subject to one year of closer Nasdaq scrutiny under Rule 5815(d)(4)(A).

The filing describes what the company intends to do next: request a hearing and argue its case. It states plainly that the outcome is not assured.

About Curis

Curis is registered with the SEC under the biological products classification, though the 8-K itself does not describe its pipeline or business beyond identifying the company and its address in Lexington, Massachusetts. Its common stock, par value $0.01 per share, trades on the Nasdaq Capital Market under the symbol CRIS.